Related Experiment Video
Updated: Jul 1, 2026
04:37
Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
Published on: May 12, 2019
Selective progesterone receptor modulators 2: use in reproductive medicine
Giuseppe Benagiano1, Carlo Bastianelli, Manuela Farris
1University 'la Sapienza', Postgraduate School of Gynaecology and Obstetrics, Policlinico Umberto I degrees , Viale Regina Margherita 245, 00161 Roma, Italy.
Expert Opinion on Pharmacotherapy
|September 10, 2008
Summary
Selective progesterone receptor modulators (SPRMs) offer diverse reproductive medicine applications. While many exist, few, like emergency contraception and treatments for uterine fibroids and endometriosis, show significant clinical promise outside pregnancy.
Area of Science:
- Reproductive Medicine
- Endocrinology
- Pharmacology
Background:
- Synthetic compounds, known as selective progesterone receptor modulators (SPRMs), interact with progesterone receptors, displaying varied agonist and antagonist activities.
- While hundreds of SPRMs exist, only a limited number have undergone substantial clinical evaluation.
Purpose of the Study:
- To review the clinical applications of SPRMs beyond pregnancy.
- To evaluate the efficacy and potential of various SPRMs, including mifepristone and others, for reproductive health indications.
Main Methods:
- Comprehensive literature review of major review papers and recent publications on SPRMs.
- Focus on indications outside of pregnancy, assessing data for multiple SPRMs.
Main Results:
- SPRMs are investigated for oral contraception, cycle control, emergency contraception, uterine fibroids, endometriosis, premenstrual syndrome, and ovarian stimulation for IVF.
- Mifepristone, asoprisnil, onapristone, ulipristal, Proellex(), ORG 33628, and ORG 31710 are among the evaluated SPRMs.
Conclusions:
- Outside of pregnancy, SPRMs show potential for large-scale use in emergency contraception.
- Long-term medical management of uterine fibroids and endometriosis are also promising applications for SPRMs.
Related Concept Videos
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:21Intrauterine Drug Delivery Systems
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:22Hormonal Regulation of the Menstrual Cycle
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH release.